The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
BUSINESS
Kyowa Kirin Development Chief Hanai Set to Become Company President
Kyowa Hakko Kirin announced on January 31 that Nobuo Hanai, Senior Managing Executive Managing Officer and Chief Director, Development Division (business development), has been tentatively designated to become its next president and representative director. Speaking to reporters on the same…
To read the full story
Related Article
BUSINESS
- 25 Japan Drug Makers’ Total Operating Profit Tops 2 Trillion Yen for 1st Time: Tally
May 20, 2025
- Chugai’s PNH Drug PiaSky Approved in Taiwan
May 20, 2025
- Japan’s Big 4 Wholesalers Log Operating Margin of 1.24%, All Break 1% Mark: Tally
May 19, 2025
- Sawai Wins Lawsuit over CML Use in Sprycel Generic
May 19, 2025
- Boehringer Ingelheim, Kanagawa Join Hands in Disease Prevention
May 19, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…